Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same

Abstract

Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include modulating CCR3, e.g., by modulating eotaxin-1/CCR3 interaction, in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.

1 . A method of treating an adult mammal for an aging-associated impairment, the method comprising:
 modulating CCR3 in the mammal in a manner sufficient to treat the adult mammal for the aging-associated impairment.   
     
     
         2 . The method according to  claim 1 , wherein modulating CCR3 comprising modulating eotaxin-1/CCR3 interaction. 
     
     
         3 . The method according to  claim 2 , wherein eotaxin-1/CCR3 interaction is modulated by reducing active systemic eotaxin-1 in the mammal. 
     
     
         4 . The method according to  claim 3 , wherein the active systemic eotaxin-1 is reduced in the mammal by administering to the mammal an effective amount of an active systemic eotaxin-1 reducing agent. 
     
     
         5 . The method according to  claim 4 , wherein the active systemic eotaxin-1 reducing agent is an eotaxin-1 binding agent. 
     
     
         6 . The method according to  claim 5 , wherein the eotaxin-1 binding agent comprises an antibody or binding fragment thereof. 
     
     
         7 . The method according to  claim 5 , wherein the eotaxin-1 binding agent comprises a small molecule. 
     
     
         8 . The method according to  claim 4 , wherein the active systemic eotaxin-1 reducing agent comprises an eotaxin-1 expression inhibitory agent. 
     
     
         9 . The method according to  claim 8 , wherein the eotaxin-1 expression inhibitory agent comprises a nucleic acid. 
     
     
         10 . The method according to  claim 1 , wherein eotaxin-1/CCR3 interaction is modulated by reducing CCR3 activity in the mammal. 
     
     
         11 . The method according to  claim 10 , wherein the CCR3 activity is reduced in the mammal by administering to the mammal an effective amount of an active CCR3 reducing agent. 
     
     
         12 . The method according to  claim 11 , wherein the active CCR3 reducing agent is a CCR3 binding agent. 
     
     
         13 . The method according to  claim 12 , wherein the CCR3 binding agent comprises an antibody or binding fragment thereof. 
     
     
         14 . The method according to  claim 12 , wherein the CCR3 binding agent comprises a small molecule. 
     
     
         15 . The method according to  claim 11 , wherein the active CCR3 reducing agent comprises a CCR3 expression inhibitory agent. 
     
     
         16 . The method according to  claim 15 , wherein the CCR3 expression inhibitory agent comprises a nucleic acid. 
     
     
         17 . The method according to  claim 1 , wherein the mammal is a primate. 
     
     
         18 . The method according to  claim 17 , wherein the primate is a human. 
     
     
         19 . The method according to  claim 1 , wherein the adult mammal is an elderly mammal. 
     
     
         20 . The method according to  claim 19 , wherein the elderly mammal is a human that is 60 years or older. 
     
     
         21 . The method according to  claim 1 , wherein the aging-associated impairment comprises a cognitive impairment. 
     
     
         22 . The method according to  claim 1 , wherein the adult mammal suffers from an aging associated disease condition. 
     
     
         23 . The method according to  claim 1 , wherein the aging associated disease condition is a cognitive decline disease condition.